Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benznidazole and E1224 DDI Study in Healthy Volunteers
NCT03892213Phase 1Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Oct 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fosravuconazole in Chagas disease, sponsored by Drugs for Neglected Diseases initiative. Primary endpoints: Maximum serum concentration of Benznidazole at Day 9 and Time of occurrence of maximum plasma concentration of Benznidazole at Day 9. Started Oct 2014; status: completed.
02
Drugs
fosravuconazole
03
Conditions
Chagas disease
Beyond the preview
Go deeper on NCT03892213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03892213.